Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anna L. Eichenberger"'
Autor:
Benjamin Speich, Frédérique Chammartin, Daniel Smith, Marcel P. Stoeckle, Patrizia Amico, Anna L. Eichenberger, Barbara Hasse, Macé M. Schuurmans, Thomas Müller, Michael Tamm, Michael Dickenmann, Irene A. Abela, Alexandra Trkola, Hans H. Hirsch, Oriol Manuel, Matthias Cavassini, Lars G. Hemkens, Matthias Briel, Nicolas J. Mueller, Andri Rauch, Huldrych F. Günthard, Michael T. Koller, Heiner C. Bucher, Katharina Kusejko, in collaboration with the study groups from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-16 (2021)
Abstract Background Late 2019, a new highly contagious coronavirus SARS-CoV-2 has emerged in Wuhan, China, causing within 2 months a pandemic with the highest disease burden in elderly and people with pre-existing medical conditions. The pandemic has
Externí odkaz:
https://doaj.org/article/2128b74ef7444eeeafbfd6921999843a
Autor:
Frédérique Chammartin, Katharina Kusejko, Chloé Pasin, Alexandra Trkola, Matthias Briel, Patrizia Amico, Marcel P. Stoekle, Anna L. Eichenberger, Barbara Hasse, Dominique L. Braun, Macé M. Schuurmans, Thomas F. Müller, Michael Tamm, Nicolas J. Mueller, Andri Rauch, Michael T. Koller, Huldrych F. Günthard, Heiner C. Bucher, Benjamin Speich, Irene A. Abela
Publikováno v:
Chammartin, Frédérique; Kusejko, Katharina; Pasin, Chloé; Trkola, Alexandra; Briel, Matthias; Amico, Patrizia; Stoekle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Mueller, Nicolas J; Rauch, Andri; Koller, Michael T; Günthard, Huldrych F; Bucher, Heiner C; Speich, Benjamin and Abela, Irene A (2022). Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV. AIDS, 36(10), pp. 1465-1468. Lippincott Williams & Wilkins 10.1097/QAD.0000000000003246
We identified determinants of SARS-CoV-2 mRNA vaccine antibody response in people with HIV (PWH). Antibody response was higher among PWH less than 60 years, with CD4+ cell count superior to 350 cells/μl and vaccinated with mRNA-1273 by Moderna compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::603866480ee84784db7152478c793fa8
Autor:
Benjamin, Speich, Frédérique, Chammartin, Irene A, Abela, Patrizia, Amico, Marcel P, Stoeckle, Anna L, Eichenberger, Barbara, Hasse, Dominique L, Braun, Macé M, Schuurmans, Thomas F, Müller, Michael, Tamm, Annette, Audigé, Nicolas J, Mueller, Andri, Rauch, Huldrych F, Günthard, Michael T, Koller, Alexandra, Trkola, Matthias, Briel, Katharina, Kusejko, Heiner C, Bucher, Patrick, Yerly
Publikováno v:
Speich, Benjamin; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Briel, Matthias; Kusejko, Katharina and Bucher, Heiner C (2022). Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical infectious diseases, 75(1), e585-e593. Oxford University Press 10.1093/cid/ciac169
Background BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Head-to-head comparison of the efficacy of these vaccines in immun
Autor:
Marc Huguenot, Andreas Neumayr, Chistroph Hatz, Anna L. Eichenberger, Andri Rauch, Cornelia Staehelin, Eva Diamantis-Karamitopoulou, Annina Elisabeth Buechi
Publikováno v:
BMC Infectious Diseases
Eichenberger, Anna; Buechi, Annina E; Neumayr, Andreas; Hatz, Chistroph; Rauch, Andri; Huguenot, Marc; Diamantis-Karamitopoulou, Eva; Staehelin, Cornelia Johanna (2017). A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure. BMC infectious diseases, 17(1), p. 81. BioMed Central 10.1186/s12879-017-2192-4
Eichenberger, Anna; Buechi, Annina E; Neumayr, Andreas; Hatz, Chistroph; Rauch, Andri; Huguenot, Marc; Diamantis-Karamitopoulou, Eva; Staehelin, Cornelia Johanna (2017). A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure. BMC infectious diseases, 17(1), p. 81. BioMed Central 10.1186/s12879-017-2192-4
BACKGROUND Visceral leishmaniasis (VL) is a protozoan disease, which is responsible for 200.000-400.000 yearly infections worldwide. If left untreated, the fatality rate can be as high as 100% within 2 years. 90% of cases occur in just six countries: